Phosphatidylcholine-Based Nanoformulation of Ergosterol Peroxide Enhances Anticancer Efficacy in Cervical Cancer Models
Pharmaceutics · 12.11.2026 · 18 (11) · 1468
DOI: 10.3390/pharmaceutics18111468 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 12.11.2026. Verfasst von Yijie Li und 4 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region, Science and Technology Major Project of Xinjiang Uygur Autonomous Region, Scientific Research Cooperation Project between Jia Yin Hospital and Xinjiang University.
Abstract (Originalsprache)
Background/Objectives: As a fungus-sourced sterol endoperoxide, ergosterol peroxide possesses extensive antitumor properties. However, unfavorable aqueous solubility, rapid in vivo clearance, and poor accumulation within tumor sites constitute major obstacles restricting its progression toward clinical application.
Methods
Herein, we constructed a novel phospholipid nanoformulation by supramolecular self-assembly of ergosterol peroxide with soybean phosphatidylcholine via a thin-film dispersion method.
Results
The optimized ergosterol peroxide–soybean phosphatidylcholine nanoformulation exhibited a uniform spherical morphology (~98 nm), excellent colloidal stability in serum-containing medium, and pH-responsive drug release behavior. In vitro, the ergosterol peroxide–soybean phosphatidylcholine nanoformulation demonstrated significantly enhanced cellular uptake in HeLa cervical cancer cells compared with free ergosterol peroxide, achieving markedly superior antiproliferative and pro-apoptotic efficacy through amplified reactive oxygen species generation. Furthermore, the ergosterol peroxide–soybean phosphatidylcholine nanoformulation effectively induced immunogenic-cell-death-associated damage-associated molecular patterns. In TC-1 tumor-bearing mice, intravenous administration of the ergosterol peroxide–soybean phosphatidylcholine nanoformulation exhibited potent dose-dependent antitumor efficacy, with biodistribution analysis confirming enhanced intratumoral ergosterol peroxide accumulation via the enhanced permeability and retention effect. Of particular note, ergosterol peroxide–soybean phosphatidylcholine nanoformulation treatment led to a substantial increase in the abundance of splenic B cells, NK cells, CD4+ helper T-cells and CD8+ cytotoxic T-cells; hematology testing together with histopathological examination further demonstrated only marginal systemic toxicity after treatment.
Conclusions
Collectively, this soybean phosphatidylcholine-based nanoplatform provides a feasible and promising pharmaceutical strategy for overcoming the inherent delivery limitations of ergosterol peroxide, offering a potential candidate for cervical cancer treatment.
Förderung
- Natural Science Foundation of Xinjiang Uygur Autonomous Region
- Science and Technology Major Project of Xinjiang Uygur Autonomous Region
- Scientific Research Cooperation Project between Jia Yin Hospital and Xinjiang University
Zitieren
APA
Li, Y., Adiljan, N., Wu, Y., Fan, Z., & Huang, W. (2026). Phosphatidylcholine-Based Nanoformulation of Ergosterol Peroxide Enhances Anticancer Efficacy in Cervical Cancer Models. Pharmaceutics, 18(11), 1468. https://doi.org/10.3390/pharmaceutics18111468
Vancouver
Li Y, Adiljan N, Wu Y, Fan Z, Huang W. Phosphatidylcholine-Based Nanoformulation of Ergosterol Peroxide Enhances Anticancer Efficacy in Cervical Cancer Models. Pharmaceutics. 2026;18(11):1468. doi:10.3390/pharmaceutics18111468
BibTeX
@article{Li2026,
author = {Li, Yijie and Adiljan, Nigare and Wu, Yulin and Fan, Zhongxiong and Huang, Weidong},
title = {Phosphatidylcholine-Based Nanoformulation of Ergosterol Peroxide Enhances Anticancer Efficacy in Cervical Cancer Models},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {11},
pages = {1468},
doi = {10.3390/pharmaceutics18111468}
}
EUVIMED